Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07293546
PHASE1/PHASE2

Phase 1/2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients With FOXG1 Syndrome (FS)

Sponsor: FOXG1 Research Foundation

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if FRF-001 is a safe, tolerable, and efficacious treatment for children and adults with FOXG1 syndrome.

Official title: An Open-Label First-in-Human Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of FRF-001, an AAV-9 Gene Therapy Administered by Intracerebroventricular Injection in Participants With FOXG1 Syndrome

Key Details

Gender

All

Age Range

2 Years - 20 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2026-07-20

Completion Date

2029-12

Last Updated

2026-07-24

Healthy Volunteers

No

Conditions

Interventions

GENETIC

FRF-001

AAV-9 gene therapy delivered by intracerebroventricular injection

Locations (1)

Texas Children's Hospital (Baylor College of Medicine)

Houston, Texas, United States